Covered recipient · General Payments record
VLADA GROYSMAN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$3,256.21
126 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,166.26 | 125 |
| Education | $89.95 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| MERZ NORTH AMERICA, INC. | $1,230.73 | 12 |
| Allergan, Inc. | $556.42 | 27 |
| AbbVie Inc. | $242.90 | 14 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $209.60 | 13 |
| Novartis Pharmaceuticals Corporation | $205.53 | 11 |
| Janssen Biotech, Inc. | $186.54 | 11 |
| PFIZER INC. | $115.16 | 9 |
| GENZYME CORPORATION | $114.36 | 5 |
| Galderma Laboratories, L.P. | $65.49 | 5 |
| UCB, Inc. | $58.19 | 3 |
| VYNE Pharmaceuticals Inc. | $53.89 | 3 |
| Lilly USA, LLC | $52.56 | 3 |
| LEO Pharma Inc. | $39.83 | 2 |
| EPI Health, LLC | $37.50 | 3 |
| Almirall LLC | $21.60 | 1 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $18.09 | 1 |
| Amgen Inc. | $17.76 | 1 |
| Incyte Corporation | $15.09 | 1 |
| Lumenis, Inc | $14.97 | 1 |
Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VLADA GROYSMAN
NPI 1255545455 · CMS profile ID 56601
Allopathic & Osteopathic Physicians / Dermatology
HOOVER, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1255545455?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VLADA GROYSMAN, NPI 1255545455, CMS profile ID 56601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255545455?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). VLADA GROYSMAN, NPI 1255545455, CMS profile ID 56601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255545455?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- VLADA GROYSMAN, NPI 1255545455, CMS profile ID 56601, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1255545455?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
126 matching records · $3,256.21 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–126 of 126.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11.18 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812702459 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $18.09 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849568907 | CMS |
| Amgen Inc. | $17.76 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826453081 | CMS |
| PFIZER INC. | $12.65 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832520769 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $11.54 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851937537 | CMS |
| AbbVie Inc. | $12.98 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794683031 | CMS |
| Allergan, Inc. | $17.32 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792791383 | CMS |
| MERZ NORTH AMERICA, INC. | $87.37 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846672867 | CMS |
| Allergan, Inc. | $28.15 | 03/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792791381 | CMS |
| Lumenis, Inc | $14.97 | 03/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 780079371 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $20.60 | 03/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851937549 | CMS |
| VYNE Pharmaceuticals Inc. | $15.13 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830837309 | CMS |
| Allergan, Inc. | $12.08 | 02/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792791379 | CMS |
| Janssen Biotech, Inc. | $11.06 | 02/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788041345 | CMS |
| MERZ NORTH AMERICA, INC. | $17.94 | 02/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846672865 | CMS |
| PFIZER INC. | $12.69 | 02/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832499545 | CMS |
| Allergan, Inc. | $3.42 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792791377 | CMS |
| Allergan, Inc. | $14.69 | 02/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792791375 | CMS |
| Novartis Pharmaceuticals Corporation | $24.55 | 02/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812702457 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $9.82 | 02/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851937539 | CMS |
| Novartis Pharmaceuticals Corporation | $11.43 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812702455 | CMS |
| Janssen Biotech, Inc. | $5.78 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788041349 | CMS |
| PFIZER INC. | $13.01 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832509742 | CMS |
| AbbVie Inc. | $13.77 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794683027 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $20.57 | 01/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851937547 | CMS |
| Novartis Pharmaceuticals Corporation | $24.34 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812702453 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $15,334.10 | 1 |
| PY2025 | Principal investigator | $2,468,508.01 | 555 |
| PY2024 | Recipient | $137,724.30 | 1 |
| PY2024 | Principal investigator | $1,824,407.26 | 503 |
| PY2023 | Principal investigator | $795,032.19 | 386 |
| PY2022 | Principal investigator | $682,362.02 | 131 |
| PY2021 | Principal investigator | $809,515.09 | 64 |
| PY2020 | Recipient | $9,403.00 | 9 |
| PY2020 | Principal investigator | $401,615.51 | 68 |
| PY2019 | Principal investigator | $53,326.65 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
556 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $11,535.00 | 12/31/2025 | Non-covered Recipient Entity Cahaba dermatology Skin Health Center | A PHASE 3 MULTICENTER LONGTERM OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO PEDIATRIC PARTICIPANTS AGED 2 YEARS AND OLDER WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228806289 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,593.00 | 12/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373206 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,867.90 | 12/22/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226158007 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,268.12 | 12/22/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226158011 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $52,153.00 | 12/22/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226158016 |
| Principal investigator 1 | Incyte Corporation | $2,949.30 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240511049 |
| Principal investigator 1 | Incyte Corporation | $1,233.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511055 |
| Principal investigator 1 | Incyte Corporation | $1,750.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511080 |
| Principal investigator 1 | Incyte Corporation | $1,750.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511085 |
| Principal investigator 1 | Incyte Corporation | $1,792.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511089 |
| Principal investigator 1 | Incyte Corporation | $2,700.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511117 |
| Principal investigator 1 | Incyte Corporation | $1,658.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511192 |
| Principal investigator 1 | Incyte Corporation | $1,658.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511197 |
| Principal investigator 1 | Incyte Corporation | $1,658.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511203 |
| Principal investigator 1 | Incyte Corporation | $1,658.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511207 |
| Principal investigator 1 | Incyte Corporation | $1,658.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511210 |
| Principal investigator 1 | Incyte Corporation | $1,658.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511216 |
| Principal investigator 1 | Incyte Corporation | $1,658.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511221 |
| Principal investigator 1 | Incyte Corporation | $182.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511229 |
| Principal investigator 1 | Incyte Corporation | $1,883.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511233 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511278 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511282 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511286 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511290 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511293 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511298 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511302 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511306 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511309 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511314 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511317 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511320 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511324 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511328 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511331 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511334 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511339 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511342 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511347 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511350 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511355 |
| Principal investigator 1 | Incyte Corporation | $1,706.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511402 |
| Principal investigator 1 | Incyte Corporation | $1,706.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511406 |
| Principal investigator 1 | Incyte Corporation | $1,706.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511412 |
| Principal investigator 1 | Incyte Corporation | $1,706.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511417 |
| Principal investigator 1 | Incyte Corporation | $1,706.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511422 |
| Principal investigator 1 | Incyte Corporation | $1,706.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511428 |
| Principal investigator 1 | Incyte Corporation | $1,706.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511434 |
| Principal investigator 1 | Incyte Corporation | $2,288.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511440 |
| Principal investigator 1 | Incyte Corporation | $2,288.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511445 |
| Principal investigator 1 | Incyte Corporation | $2,369.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511452 |
| Principal investigator 1 | Incyte Corporation | $2,369.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511457 |
| Principal investigator 1 | Incyte Corporation | $2,369.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511463 |
| Principal investigator 1 | Incyte Corporation | $2,369.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511471 |
| Principal investigator 1 | Incyte Corporation | $355.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511477 |
| Principal investigator 1 | Incyte Corporation | $2,430.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511483 |
| Principal investigator 1 | Incyte Corporation | $1,343.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511813 |
| Principal investigator 1 | Incyte Corporation | $1,343.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511818 |
| Principal investigator 1 | Incyte Corporation | $1,424.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511826 |
| Principal investigator 1 | Incyte Corporation | $1,424.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511832 |
| Principal investigator 1 | Incyte Corporation | $1,424.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511837 |
| Principal investigator 1 | Incyte Corporation | $1,424.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511842 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 12/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511853 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $939.90 | 12/17/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289880 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $164.88 | 12/08/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226158003 |
| Principal investigator 1 | Incyte Corporation | $20,294.60 | 12/05/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511172 |
| Principal investigator 1 | ABBVIE INC. | $37,323.80 | 12/04/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202528036 |
| Principal investigator 1 | ABBVIE INC. | $12,121.70 | 12/04/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202528038 |
| Principal investigator 1 | Incyte Corporation | $9,839.20 | 12/04/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511041 |
| Principal investigator 1 | Incyte Corporation | $2,846.80 | 12/04/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240511045 |
| Principal investigator 1 | Incyte Corporation | $10,244.00 | 12/04/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511058 |
| Principal investigator 1 | Incyte Corporation | $2,124.00 | 12/04/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511063 |
| Principal investigator 1 | Incyte Corporation | $3,375.00 | 12/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511225 |
| Principal investigator 1 | Incyte Corporation | $154.00 | 12/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511362 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,669.50 | 12/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289017 |
| Principal investigator 1 | ABBVIE INC. | $62.50 | 11/26/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202525450 |
| Principal investigator 1 | Incyte Corporation | $3,267.00 | 11/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511032 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511109 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511114 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511122 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511124 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511127 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511130 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511134 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511138 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511143 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511147 |
| Principal investigator 1 | Incyte Corporation | $1,539.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511152 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511160 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511163 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511168 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511237 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511494 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511500 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511505 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511511 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511516 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511522 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511528 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511536 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511542 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511548 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511553 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511558 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511564 |
| Principal investigator 1 | Incyte Corporation | $1,559.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511595 |
| Principal investigator 1 | Incyte Corporation | $1,559.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511601 |
| Principal investigator 1 | Incyte Corporation | $1,559.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511606 |
| Principal investigator 1 | Incyte Corporation | $1,559.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511612 |
| Principal investigator 1 | Incyte Corporation | $1,305.00 | 11/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511618 |
| Principal investigator 1 | ABBVIE INC. | $62.61 | 11/20/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202525014 |
| Principal investigator 1 | Incyte Corporation | $723.60 | 11/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511023 |
| Principal investigator 1 | PFIZER INC. | $1,525.31 | 11/18/2025 | Non-covered Recipient Entity Cahaba Dermatology Skin Health Center LLC | PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 | No dispute reported | 06/30/2026 | 1228806284 |
| Principal investigator 1 | Incyte Corporation | $1,233.00 | 11/14/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511018 |
| Principal investigator 1 | ABBVIE INC. | $445.90 | 11/12/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202523905 |
| Principal investigator 1 | Incyte Corporation | $387.00 | 11/12/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240511625 |
| Principal investigator 1 | Incyte Corporation | $361.80 | 11/07/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511026 |
| Principal investigator 1 | Incyte Corporation | $1,446.30 | 11/07/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240511037 |
| Principal investigator 1 | ABBVIE INC. | $5,200.00 | 11/06/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202523217 |
| Principal investigator 1 | ABBVIE INC. | $110.50 | 11/06/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202523219 |
| Principal investigator 1 | ABBVIE INC. | $7,500.00 | 11/06/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202523533 |
| Principal investigator 1 | ABBVIE INC. | $21,579.50 | 11/05/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202521491 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,420.10 | 11/05/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223288065 |
| Principal investigator 1 | ABBVIE INC. | $12,519.70 | 11/04/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202520173 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $900.00 | 11/04/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157993 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $5,500.00 | 10/27/2025 | Non-covered Recipient Entity Cahaba Dermatology and Skin Health Center LLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163720 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $38,931.00 | 10/27/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157980 |
| Principal investigator 1 | Incyte Corporation | $3,375.00 | 10/24/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511274 |
| Principal investigator 1 | Incyte Corporation | $1,322.10 | 10/24/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240511395 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,175.00 | 10/24/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373200 |
| Principal investigator 1 | Janssen Research & Development, LLC | $420.00 | 10/24/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373214 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $60.00 | 10/24/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287657 |
| Principal investigator 1 | Incyte Corporation | $1,504.80 | 10/23/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510994 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511067 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511072 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511077 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511093 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511097 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511101 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511105 |
| Principal investigator 1 | Incyte Corporation | $42.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511242 |
| Principal investigator 1 | Incyte Corporation | $54.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511247 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511250 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511254 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511258 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511262 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511266 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511270 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511367 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511373 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511377 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511384 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511390 |
| Principal investigator 1 | Incyte Corporation | $2,369.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511488 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511570 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511576 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511582 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511588 |
| Principal investigator 1 | Incyte Corporation | $1,539.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511631 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511637 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511644 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511650 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511655 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511663 |
| Principal investigator 1 | Incyte Corporation | $1,166.70 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511669 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511676 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511681 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511687 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511692 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511697 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511704 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511712 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511716 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511721 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511726 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511732 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511738 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511744 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511749 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511758 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511765 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511771 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511778 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511784 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511790 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511795 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511802 |
| Principal investigator 1 | Incyte Corporation | $1,559.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240511806 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287169 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287171 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223287173 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,695.90 | 10/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287255 |
| Principal investigator 1 | ABBVIE INC. | $42.90 | 10/21/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202517495 |
| Principal investigator 1 | ABBVIE INC. | $42.90 | 10/21/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202517523 |
| Principal investigator 1 | ABBVIE INC. | $9,894.30 | 10/21/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202517525 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,550.00 | 10/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $116.00 | 10/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373182 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,195.00 | 10/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373221 |
| Principal investigator 1 | Incyte Corporation | $1,233.00 | 10/16/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510998 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 10/16/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240511015 |
| Principal investigator 1 | Eli Lilly and Company | $12,530.00 | 10/15/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187876205 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $455.36 | 10/14/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157973 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,400.00 | 10/14/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157977 |
| Principal investigator 1 | ABBVIE INC. | $5,620.80 | 10/09/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202514421 |
| Principal investigator 1 | ABBVIE INC. | $21,559.90 | 10/09/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202514423 |
| Principal investigator 1 | Incyte Corporation | $1,233.00 | 10/09/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511007 |
| Principal investigator 1 | Incyte Corporation | $1,525.50 | 10/09/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240511011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,680.00 | 10/06/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373142 |
| Principal investigator 1 | Incyte Corporation | $1,979.10 | 10/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240511002 |
| Principal investigator 1 | Incyte Corporation | $1.96 | 10/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240511155 |
| Principal investigator 1 | Incyte Corporation | $7.63 | 10/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240511176 |
| Principal investigator 1 | Incyte Corporation | $7.63 | 10/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240511179 |
| Principal investigator 1 | Incyte Corporation | $7.63 | 10/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240511184 |
| Principal investigator 1 | Incyte Corporation | $7.63 | 10/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240511189 |
| Principal investigator 1 | Incyte Corporation | $57.85 | 10/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240511846 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,343.00 | 09/29/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE NTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373150 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,408.20 | 09/26/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285981 |
| Principal investigator 1 | Incyte Corporation | $42.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510709 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510714 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510717 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510721 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510724 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510729 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510733 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510735 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510739 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510744 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510748 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510752 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510756 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510760 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510764 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510769 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510774 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510778 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510781 |
| Principal investigator 1 | Incyte Corporation | $216.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510787 |
| Principal investigator 1 | Incyte Corporation | $81.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510792 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510797 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510801 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510804 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510808 |
| Principal investigator 1 | Incyte Corporation | $216.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510813 |
| Principal investigator 1 | Incyte Corporation | $81.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510817 |
| Principal investigator 1 | Incyte Corporation | $81.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510820 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510824 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510830 |
| Principal investigator 1 | Incyte Corporation | $1,885.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510834 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510867 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510872 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510876 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510880 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510911 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510916 |
| Principal investigator 1 | Incyte Corporation | $241.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510920 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510924 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510928 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510932 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510937 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510943 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510948 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510953 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510957 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510962 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510965 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510980 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510984 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510986 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 09/25/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510990 |
| Principal investigator 1 | Incyte Corporation | $4,592.70 | 09/23/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510646 |
| Principal investigator 1 | ABBVIE INC. | $4,483.70 | 09/18/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202511572 |
| Principal investigator 1 | Incyte Corporation | $1,143.00 | 09/18/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510639 |
| Principal investigator 1 | Incyte Corporation | $3,958.20 | 09/18/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510650 |
| Principal investigator 1 | Incyte Corporation | $3,699.00 | 09/12/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510642 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $4,828.95 | 09/11/2025 | Non-covered Recipient Entity Cahaba Dermatology and Skin Health Center LLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163718 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,112.50 | 09/10/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285227 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 09/10/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285229 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,129.00 | 09/08/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE NTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373174 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $700.00 | 09/08/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157951 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $220.00 | 09/08/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157957 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,500.00 | 09/08/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157960 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $49,853.00 | 09/08/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157968 |
| Principal investigator 1 | ABBVIE INC. | $28,124.60 | 09/04/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509826 |
| Principal investigator 1 | Incyte Corporation | $1,446.30 | 09/04/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510654 |
| Principal investigator 1 | ABBVIE INC. | $2,910.50 | 09/03/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202508248 |
| Principal investigator 1 | Incyte Corporation | $2,835.00 | 09/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510838 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,620.00 | 09/03/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157948 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,240.00 | 09/03/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157964 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 09/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285003 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,000.00 | 09/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285021 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,755.00 | 09/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223285023 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,808.40 | 09/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285035 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 09/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510863 |
| Principal investigator 1 | Incyte Corporation | $700.00 | 08/26/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510609 |
| Principal investigator 1 | Incyte Corporation | $1,325.70 | 08/26/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510613 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 08/26/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510617 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 08/26/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510620 |
| Principal investigator 1 | Incyte Corporation | $8,000.00 | 08/26/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510624 |
| Principal investigator 1 | Incyte Corporation | $6,502.50 | 08/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510635 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510658 |
| Principal investigator 1 | Incyte Corporation | $93.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510664 |
| Principal investigator 1 | Incyte Corporation | $93.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510668 |
| Principal investigator 1 | Incyte Corporation | $314.70 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510672 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510677 |
| Principal investigator 1 | Incyte Corporation | $93.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510681 |
| Principal investigator 1 | Incyte Corporation | $93.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510685 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510690 |
| Principal investigator 1 | Incyte Corporation | $2,724.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510694 |
| Principal investigator 1 | Incyte Corporation | $1,793.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510697 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510701 |
| Principal investigator 1 | Incyte Corporation | $1,976.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510704 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510884 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510888 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510892 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510896 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510900 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510904 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510968 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510972 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/20/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510977 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,625.00 | 08/18/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157935 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,719.00 | 08/18/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157944 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,074.15 | 08/15/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284349 |
| Principal investigator 1 | Incyte Corporation | $92.00 | 08/14/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240510907 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $20,482.00 | 08/11/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157938 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,060.40 | 08/11/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157940 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $13,763.93 | 08/07/2025 | Non-covered Recipient Entity Cahaba Dermatology and Skin Health Center LLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163716 |
| Principal investigator 1 | Incyte Corporation | $1,143.00 | 08/07/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510628 |
| Principal investigator 1 | Incyte Corporation | $1,224.90 | 08/07/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510632 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,900.00 | 08/07/2025 | Non-covered Recipient Entity Cahaba Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175163008 |
| Principal investigator 1 | ABBVIE INC. | $29,825.00 | 08/06/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202503361 |
| Principal investigator 1 | ABBVIE INC. | $8,681.88 | 08/05/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202502038 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 08/04/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510846 |
| Principal investigator 1 | Incyte Corporation | $8,000.00 | 08/04/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510855 |
| Principal investigator 1 | Amgen Inc. | $7,500.00 | 08/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) | No dispute reported | 06/30/2026 | 1246639841 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,233.35 | 08/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283611 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,309.10 | 08/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283651 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 07/31/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202500736 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,645.00 | 07/31/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE NTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373159 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,755.00 | 07/23/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223282980 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 07/23/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223282982 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,282.20 | 07/23/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283026 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,514.20 | 07/23/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283060 |
| Principal investigator 1 | Incyte Corporation | $3,628.80 | 07/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510587 |
| Principal investigator 1 | Incyte Corporation | $4,775.40 | 07/17/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510590 |
| Principal investigator 1 | Incyte Corporation | $2,109.60 | 07/17/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510604 |
| Principal investigator 1 | Incyte Corporation | $1,602.50 | 07/16/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510842 |
| Principal investigator 1 | Incyte Corporation | $1,417.00 | 07/16/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510851 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20,081.68 | 07/15/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190304177 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $53,114.00 | 07/14/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157925 |
| Principal investigator 1 | PFIZER INC. | $11,535.00 | 07/11/2025 | Non-covered Recipient Entity Cahaba Dermatology Skin Health Center LLC | PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 | No dispute reported | 06/30/2026 | 1228845659 |
| Principal investigator 1 | Incyte Corporation | $361.80 | 07/10/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510599 |
| Principal investigator 1 | Incyte Corporation | $1,233.00 | 07/04/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510594 |
| Principal investigator 1 | ABBVIE INC. | $5,568.90 | 07/02/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202495881 |
| Principal investigator 1 | ABBVIE INC. | $31,811.90 | 07/02/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202495883 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,336.00 | 07/02/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157922 |
| Principal investigator 1 | Incyte Corporation | $54.90 | 07/01/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510859 |
| Principal investigator 1 | Incyte Corporation | $9,495.90 | 06/24/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510557 |
| Recipient | Nielsen BioSciences, Inc. | $15,334.10 | 06/24/2025 | Covered Recipient Physician | CFW-3A | No dispute reported | 06/30/2026 | 1215535990 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,000.00 | 06/24/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY SKIN HEALTH CENTER LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190312439 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $8,000.00 | 06/23/2025 | Non-covered Recipient Entity Cahaba Dermatology and Skin Health Center LLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163714 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,126.00 | 06/23/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY & SKIN HEALTH CE NTER LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175373192 |
| Principal investigator 1 | Incyte Corporation | $361.80 | 06/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510544 |
| Principal investigator 1 | Incyte Corporation | $7,012.80 | 06/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510561 |
| Principal investigator 1 | Incyte Corporation | $1,275.30 | 06/18/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510565 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,717.40 | 06/18/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223281608 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $28,279.00 | 06/16/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157913 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,845.00 | 06/13/2025 | Non-covered Recipient Entity Cahaba Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175162747 |
| Principal investigator 1 | Incyte Corporation | $36,898.80 | 06/12/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510549 |
| Principal investigator 1 | Incyte Corporation | $427.50 | 06/05/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510553 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,411.10 | 06/04/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280730 |
| Principal investigator 1 | ABBVIE INC. | $2,754.70 | 06/03/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202487669 |
| Principal investigator 1 | ABBVIE INC. | $1,589.20 | 06/03/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202487685 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,430.00 | 05/27/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157910 |
| Principal investigator 1 | Incyte Corporation | $4,491.00 | 05/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240510540 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $35,942.00 | 05/19/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157918 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,630.45 | 05/16/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279924 |
| Principal investigator 1 | Incyte Corporation | $1,317.60 | 05/12/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510583 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162725 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162733 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162738 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162770 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162801 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,044.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162827 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162920 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162944 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,544.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163049 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,544.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163066 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163072 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,544.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163144 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 05/08/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163379 |
| Principal investigator 1 | ABBVIE INC. | $52,485.80 | 05/07/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202483879 |
| Principal investigator 1 | ABBVIE INC. | $1,309.00 | 05/06/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202482135 |
| Principal investigator 1 | Incyte Corporation | $1,386.90 | 04/14/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510578 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,449.20 | 04/14/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157875 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $93,515.00 | 04/14/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157903 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $21,607.30 | 04/11/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277980 |
| Principal investigator 1 | Incyte Corporation | $361.80 | 04/07/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240510534 |
| Principal investigator 1 | ABBVIE INC. | $7,161.40 | 04/03/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202469907 |
| Principal investigator 1 | ABBVIE INC. | $12,233.50 | 04/03/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202469912 |
| Principal investigator 1 | Incyte Corporation | $42.24 | 04/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510569 |
| Principal investigator 1 | Incyte Corporation | $99.12 | 04/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510573 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,590.85 | 04/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277496 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,540.14 | 03/31/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190304171 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 03/24/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163136 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 03/24/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163160 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 03/24/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163185 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 03/24/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163241 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,164.00 | 03/24/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157872 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,850.00 | 03/21/2025 | Non-covered Recipient Entity Cahaba Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175162711 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $370.00 | 03/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276815 |
| Principal investigator 1 | Incyte Corporation | $1,180.70 | 03/14/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510484 |
| Principal investigator 1 | Incyte Corporation | $2,062.00 | 03/14/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510518 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $315.00 | 03/12/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276321 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,450.00 | 03/10/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226157865 |
| Principal investigator 1 | ABBVIE INC. | $19,072.40 | 03/07/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460991 |
| Principal investigator 1 | ABBVIE INC. | $1,505.20 | 03/06/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202457914 |
| Principal investigator 1 | Incyte Corporation | $9.80 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510487 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510499 |
| Principal investigator 1 | Incyte Corporation | $15.26 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510503 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510507 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510511 |
| Principal investigator 1 | Incyte Corporation | $115.70 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510515 |
| Principal investigator 1 | Incyte Corporation | $15.26 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510521 |
| Principal investigator 1 | Incyte Corporation | $15.26 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510525 |
| Principal investigator 1 | Incyte Corporation | $15.26 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510530 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,262.00 | 03/03/2025 | Non-covered Recipient Entity Cahaba Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175163301 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $22,118.20 | 03/03/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275863 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,679.00 | 02/27/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163514 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,800.00 | 02/27/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY SKIN HEALTH CENTER LLC | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190312441 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,682.30 | 02/26/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275561 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $45,291.00 | 02/24/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157867 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,900.00 | 02/21/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275435 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162633 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162652 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162658 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162666 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162677 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162685 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162701 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162718 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162762 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162778 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162785 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162791 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162809 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162818 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162843 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162852 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162862 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162870 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162878 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162886 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162894 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162906 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162913 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162928 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162937 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162952 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162959 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162978 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162986 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162994 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162999 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163020 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163027 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163034 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163042 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163058 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163086 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163093 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163099 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163110 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163117 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163126 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163152 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163170 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163178 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163193 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163200 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163207 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163214 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163223 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163250 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163258 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163266 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163272 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163277 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163286 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163293 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163307 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163316 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163324 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163336 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163341 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163350 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163359 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163364 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163372 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163388 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163396 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163404 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163413 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163435 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163444 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163452 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163461 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163478 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163483 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163491 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163499 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163506 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163521 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163529 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163537 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163556 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,551.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163563 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163580 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163588 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163597 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,943.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163605 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,168.00 | 02/20/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163613 |
| Principal investigator 1 | Incyte Corporation | $2,062.00 | 02/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510455 |
| Principal investigator 1 | Incyte Corporation | $1,192.40 | 02/19/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510460 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,318.33 | 02/10/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190304175 |
| Principal investigator 1 | ABBVIE INC. | $23,471.60 | 02/06/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202448835 |
| Principal investigator 1 | ABBVIE INC. | $1,276.50 | 02/05/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202445377 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $27,806.20 | 02/04/2025 | Non-covered Recipient Entity Cahaba Dermatology And Skin Health Center Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226157861 |
| Principal investigator 1 | Eli Lilly and Company | $160,974.24 | 01/29/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY OF LY4100511 (DC-853) FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1187877253 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,085.00 | 01/29/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175162965 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,679.00 | 01/29/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163421 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,679.00 | 01/29/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163470 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,679.00 | 01/29/2025 | Non-covered Recipient Entity Cahaba Derm and Skin Hlth Ctr Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175163548 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $29,079.70 | 01/22/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274425 |
| Principal investigator 1 | Incyte Corporation | $1,353.90 | 01/17/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510450 |
| Principal investigator 1 | Incyte Corporation | $1,554.00 | 01/17/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510470 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $135.48 | 01/15/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190304173 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $24,678.06 | 01/07/2025 | Non-covered Recipient Entity Cahaba Dermatology & Skin Health Center -S | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis | No dispute reported | 06/30/2026 | 1248163712 |
| Principal investigator 1 | Incyte Corporation | $5,684.40 | 01/07/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240511858 |
| Principal investigator 1 | ABBVIE INC. | $3,728.20 | 01/02/2025 | Non-covered Recipient Entity CAHABA DERM & SKIN HEALTH CTR LLC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202435236 |
| Principal investigator 1 | Amgen Inc. | $78,859.23 | 01/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY AND SKIN HEALTH CENTER LLC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246639843 |
| Principal investigator 1 | Incyte Corporation | $115.62 | 01/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510463 |
| Principal investigator 1 | Incyte Corporation | $40.32 | 01/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510466 |
| Principal investigator 1 | Incyte Corporation | $134.40 | 01/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510475 |
| Principal investigator 1 | Incyte Corporation | $148.68 | 01/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510479 |
| Principal investigator 1 | Incyte Corporation | $3.93 | 01/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510491 |
| Principal investigator 1 | Incyte Corporation | $545.16 | 01/02/2025 | Non-covered Recipient Entity CAHABA DERMATOLOGY | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240510495 |